泽璟制药：注射用ZGGS34获得药物临床试验批准通知书

Core Viewpoint - Zai Jian Pharmaceutical (688266.SH) has received approval from the National Medical Products Administration for clinical trials of its injection ZGGS34, targeting MUC17 positive advanced solid tumors, indicating a significant advancement in its drug development pipeline [1] Company Summary - The drug ZGGS34 is a trispecific antibody with strong tumor-killing effects and good safety characteristics, highlighting its potential in cancer treatment [1]